BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Feb. 20, 2019
View Archived Issues
Glial alpha-synuclein causes neuronal toxicity
Read More
Decoy platelets for thrombosis, metastasis
Read More
How microbiome cell toxin damages host cell DNA
Read More
MAPK4 blockade inhibits AKT/mTOR pathway and shows promise for cancer therapy
Read More
Fatty acid transporter CD36 inhibition could be beneficial in prostate cancer
Read More
Allakos presents results from phase I study of AK-002 in indolent systemic mastocytosis
Read More
First patient dosed in phase II study of NYX-783
Read More
Gamida Cell and Editas Medicine to study CRISPR editing of NAM-NK cells
Read More
Funding continues for Aravive's anti-GAS6 fusion protein development
Read More
Discovery and characterization of novel PROTAC AR degrader, ARD-69
Read More
First-in-human results presented for SynGEM vaccine
Read More
GlaxoSmithKline Intellectual Property divulges PI3K inhibitors
Read More
Merck & Co. describes new IDO1 inhibitors
Read More
Inosine supplementation and modulation of adenosine deaminase as a potential therapy against ALS
Read More
Jazz Pharmaceuticals identifies compounds for sleep disorders
Read More
Vical discontinues phase II trial of VL-2397 as it pursues strategic alternative review process
Read More
Search for alternative Notch 1 pathway modulators leads Novartis to NVS-ZP7-4
Read More
Semma Therapeutics divulges new compositions for diabetes
Read More
GlaxoSmithKline Biologicals patents adenoviral vectors for CHIKV infections
Read More
AlzProtect completes phase I food effect study with AZP-2006
Read More
FDA approves Esperoct for hemophilia A
Read More
EZH2 inhibitors may be a means of treating scleroderma
Read More
Catabasis reports growth data from phase II trial of edasalonexent for Duchenne muscular dystrophy
Read More
ReNeuron reports vision improvement in first phase II cohort with hRPC cell therapy for RP
Read More
FDA places partial clinical hold on phase I study of XmAb-14045
Read More
Phase II trial of VAL-083 in newly diagnosed GBM achieves halfway enrollment
Read More